Calliditas Therapeutics IPO Presentation Deck

No clinically relevant change in HbA1c during Nefecon treatment Change in HbA1c from baseline to end of treatment End of treatment [mmol/mol) 20 calliditas Change in HbA1c 8 mg treatment group Baseline (mmol/mol) Note: HbA1c Measure of the risk for having diabetes. Data derived from post-hoc analyses. Data on file. End of treatment (mmol/mol) Change in HbA1c 16 mg treatment group Baseline (mmol/mol) June 2020 15

View entire presentation